People · Operator
Named in public records as an officer, director or promoter · active 2019–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TScan Therapeutics, Inc. | — | Biotechnology | Series C | $123.3M | $3.3B | 2019 |
| ImmuneID, Inc. | — | Biotechnology | Series B | $17.1M | $549.0M | 2020 |
Lea Hachigian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lea Hachigian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christoph Westphal | 2 | 8 |
| Ittai Harel | 2 | 6 |
| Campbell Murray | 1 | 9 |
| Robert Crane | 1 | 7 |
| Steve Kraus | 1 | 6 |
| Timothy Barberich | 1 | 6 |
| Andrew Hedin | 1 | 5 |
| Nandita Shangari | 1 | 4 |
| David Southwell | 1 | 3 |
| Hannes Smarason | 1 | 2 |
| Brian Silver | 1 | 2 |
| Doug Fambrough | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.